Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

Clinical trial NCT07159217 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07159217
Sponsor: Peking Union Medical College Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Biliary Tract Cancer Disitamab Vedotin Lenvatinib Immune Checkpoint Inhibitors

Start date: 2025-08-30
Primary completion: 2027-05-31
Enrollment: 65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.